# Transthyretin Cardiac Amyloidosis in HFpEF

> **NCT03414632** · EARLY_PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 287 (actual)

## Conditions studied

- Heart Failure With Preserved Ejection Fraction

## Interventions

- **DRUG:** 99mTc-PYP

## Key facts

- **NCT ID:** NCT03414632
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-01
- **Primary completion:** 2020-03-31
- **Final completion:** 2020-03-31
- **Target enrollment:** 287 (ACTUAL)
- **Last updated:** 2021-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03414632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03414632, "Transthyretin Cardiac Amyloidosis in HFpEF". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03414632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*